Studies that aim to develop strategies to improve the response rate of ICB therapy have shown that combining TLR9 agonists with anti–PD-1 ICB therapy enhances anti–PD-1 treatment in mouse models of pancreatic cancer (15) and head and neck squamous cell carcinoma (16). The gene discussed is TLR9; the disease is familial pancreatic carcinoma.